FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096161807> ?p ?o ?g. }

• W3096161807 endingPage "12" @default.
• W3096161807 startingPage "12" @default.
• W3096161807 abstract "INTRODUCTION The survival of myeloma patients has doubled the past decade, however, patients refractory to both proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) still have poor prognosis. Immunotherapy with monoclonal antibodies targeting cell-surface antigens is a promising treatment strategy with different mechanisms of action and has been integrated both in the newly diagnosed and relapsed/refractory setting. The combination of daratumumab, pomalidomide and dexamethasone (DaraPomDex) has demonstrated significant activity even in patients refractory to both drugs and a potential mechanism may be re-sensitization to pomalidomide. Another report showed that daratumumab-refractory patients who previously failed IMiD, responded when the IMiD was added to daratumumab. This provided a proof of principle that anti-CD38 antibodies can alter the underlying pathophysiology, and can potentially overcome refractoriness to IMIDs. Increased CD38 expression after IMiD exposure could be a mechanism of IMiD resistance, and anti-CD38 agents may act by eliminating this effect. Daratumumab induces clonal CD8+ T-cell expansion that may contribute to clinical responses, which is augmented by IMiDs, resulting in synergy.Potential loss of this response in progressing patients may be recaptured after the reintroduction of IMiDs. Another potential mechanism could involve the reemergence of IMiD-sensitive clones after an IMiD-free period. There is data that daratumumab alters the tumor immune microenvironment, and this effect may be long lasting , even after daratumumab discontinuation . The aim of the study was to evaluate the efficacy of re-treatment with IMiD-based therapy in patients refractory both to IMiDs and anti-CD38 antibodies. PATIENTS AND METHODS The study included 38 patients who were refractory to antiCD-38-based therapy and to at least one IMiD. Overall, 26 (68%) patients had received lenalidomide, 11 (29%) pomalidomide and 1 (3%) thalidomide before anti-CD38 treatment. RESULTS Median number of prior lines before IMiD retreatment was 4 (range 2 to 13). The patient distribution per R-ISS was: R-ISS 1: 8, R-ISS 2: 9, R-ISS 3: 4. Overall, 4 (11%) patients received lenalidomide-, 33 (86.5%) pomalidomide-, and 1 (2.5%) thalidomide-based regimens post anti-CD38. The majority of patients were treated with pomalidomide-cyclophosphamide-dexamethasone (PCD) (n=13) and pomalidomide-dexamethasone (PomD) (n=11). The remaining 14 patients were treated with other IMiD-based triplets. Importantly, 10 (26%) patients received the same IMiD as prior to anti-CD38 exposure (lenalidomide n=2, pomalidomide n=8). Median time from diagnosis to IMiD re-treatment was 61.5 months. Overall, 20 patients (53%) achieved a response during IMiD retreatment, including CR=1, VGPR=5, PR=10 and MR=4; 11 patients achieved SD, whereas 7 patients progressed. The disease control rate (DCR=SD+PR+VGPR+CR) was 82%. Among the patients re-exposed to the same IMiD, 5 responded, 3 progressed and 2 remained stable. Among the responders, 1 achieved VGPR with PCD, 2 PR with PCD and DaraPomDex, whereas 2 showed MR with PCD and PCD with Bortezomib. 79% (22/28) of the patients received pomalidomide following previous exposure to lenalidomide; among them, 15/22 (68%) patients responded (1 CR, 4 VGPR, 8 PR, 2 MR), 3 remained stable and 4 progressed. Interestingly, 10 out of 13 (77%) patients who received PCD responded. Median PFS for all patients was 4 months (range 2.9-4.8). Median time to next treatment (TtNT) for the whole study cohort as well as for those who received the same IMiD pre- and post-exposure to anti-CD38 was 4.2 months as well. Median duration of response (DoR) for the responders was 7 months. Median TtNT for those who received pomalidomide after previous exposure to lenalidomide (n=22) was 3.9 months; median DoR among the responders was 6.6 months. Median OS 5.3 range 0.5-35.5. CONCLUSION IMiD retreatment in patients refractory to both an IMiD and an anti-CD38 antibody can induce significant response rates, even among patients re-exposed to the same IMiD. This indicates that after anti-CD38 therapy a long lasting, probably immunomodulatory effect may be associated with some degree of re-sensitization to IMiDs. The subgroup of patients receiving PCD derived the most benefit. In this context, a prospective study evaluating the role of PCD in this population is currently ongoing. Disclosures Gavriatopoulou: Amgen: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria; Genesis Pharma: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Takeda: Consultancy, Honoraria. Terpos:Amgen: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Takeda: Honoraria, Other: Travel expenses, Research Funding; Genesis: Honoraria, Other: Travel expenses, Research Funding; Celgene: Honoraria; Sanofi: Honoraria; BMS: Honoraria. Kastritis:Takeda: Consultancy, Honoraria, Other: Travel/accommodations/expenses; Pfizer: Consultancy; Janssen: Consultancy, Honoraria, Other: Travel/accommodations/expenses, Research Funding; Genesis Pharma: Consultancy, Honoraria, Other: Travel/accommodations/expenses; Amgen: Consultancy, Honoraria, Research Funding. Dimopoulos:Takeda: Honoraria; Amgen: Honoraria; Celgene: Honoraria; Janssen: Honoraria; Bristol-Myers Squibb: Honoraria; Beigene: Honoraria." @default.
• W3096161807 created "2020-11-09" @default.
• W3096161807 creator A5018522443 @default.
• W3096161807 creator A5020827486 @default.
• W3096161807 creator A5024471527 @default.
• W3096161807 creator A5027500108 @default.
• W3096161807 creator A5033282728 @default.
• W3096161807 creator A5041407463 @default.
• W3096161807 creator A5047107290 @default.
• W3096161807 creator A5059359090 @default.
• W3096161807 creator A5065602436 @default.
• W3096161807 creator A5083511911 @default.
• W3096161807 creator A5088691462 @default.
• W3096161807 creator A5090511737 @default.
• W3096161807 date "2020-11-05" @default.
• W3096161807 modified "2023-10-16" @default.
• W3096161807 title "IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure" @default.
• W3096161807 doi "https://doi.org/10.1182/blood-2020-136248" @default.
• W3096161807 hasPublicationYear "2020" @default.
• W3096161807 type Work @default.
• W3096161807 sameAs 3096161807 @default.
• W3096161807 citedByCount "0" @default.
• W3096161807 crossrefType "journal-article" @default.
• W3096161807 hasAuthorship W3096161807A5018522443 @default.
• W3096161807 hasAuthorship W3096161807A5020827486 @default.
• W3096161807 hasAuthorship W3096161807A5024471527 @default.
• W3096161807 hasAuthorship W3096161807A5027500108 @default.
• W3096161807 hasAuthorship W3096161807A5033282728 @default.
• W3096161807 hasAuthorship W3096161807A5041407463 @default.
• W3096161807 hasAuthorship W3096161807A5047107290 @default.
• W3096161807 hasAuthorship W3096161807A5059359090 @default.
• W3096161807 hasAuthorship W3096161807A5065602436 @default.
• W3096161807 hasAuthorship W3096161807A5083511911 @default.
• W3096161807 hasAuthorship W3096161807A5088691462 @default.
• W3096161807 hasAuthorship W3096161807A5090511737 @default.
• W3096161807 hasBestOaLocation W30961618071 @default.
• W3096161807 hasConcept C126322002 @default.
• W3096161807 hasConcept C142424586 @default.
• W3096161807 hasConcept C143998085 @default.
• W3096161807 hasConcept C203014093 @default.
• W3096161807 hasConcept C2776364478 @default.
• W3096161807 hasConcept C2777478702 @default.
• W3096161807 hasConcept C2778524551 @default.
• W3096161807 hasConcept C2781119759 @default.
• W3096161807 hasConcept C71924100 @default.
• W3096161807 hasConcept C86803240 @default.
• W3096161807 hasConcept C87355193 @default.
• W3096161807 hasConceptScore W3096161807C126322002 @default.
• W3096161807 hasConceptScore W3096161807C142424586 @default.
• W3096161807 hasConceptScore W3096161807C143998085 @default.
• W3096161807 hasConceptScore W3096161807C203014093 @default.
• W3096161807 hasConceptScore W3096161807C2776364478 @default.
• W3096161807 hasConceptScore W3096161807C2777478702 @default.
• W3096161807 hasConceptScore W3096161807C2778524551 @default.
• W3096161807 hasConceptScore W3096161807C2781119759 @default.
• W3096161807 hasConceptScore W3096161807C71924100 @default.
• W3096161807 hasConceptScore W3096161807C86803240 @default.
• W3096161807 hasConceptScore W3096161807C87355193 @default.
• W3096161807 hasIssue "Supplement 1" @default.
• W3096161807 hasLocation W30961618071 @default.
• W3096161807 hasOpenAccess W3096161807 @default.
• W3096161807 hasPrimaryLocation W30961618071 @default.
• W3096161807 hasRelatedWork W2021159149 @default.
• W3096161807 hasRelatedWork W2035684047 @default.
• W3096161807 hasRelatedWork W2608137803 @default.
• W3096161807 hasRelatedWork W2612717195 @default.
• W3096161807 hasRelatedWork W2731606591 @default.
• W3096161807 hasRelatedWork W2951912930 @default.
• W3096161807 hasRelatedWork W2980500792 @default.
• W3096161807 hasRelatedWork W2980591007 @default.
• W3096161807 hasRelatedWork W3016534082 @default.
• W3096161807 hasRelatedWork W3116433611 @default.
• W3096161807 hasVolume "136" @default.
• W3096161807 isParatext "false" @default.
• W3096161807 isRetracted "false" @default.
• W3096161807 magId "3096161807" @default.
• W3096161807 workType "article" @default.